Numerous studies have focused on the investigation of biomarkers and molecular mechanisms of pancreatic cancers, and it is demonstrated that accumulated mutations in genes like oncogene Kras, and tumor-suppressor genes including P16 as well as TP53 resulted in the occurrence of pancreatic cancer [4]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.